Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

1,569 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Measurement of hepatitis B virus core-related antigen is valuable for identifying patients who are at low risk of lamivudine resistance.
Tanaka E, Matsumoto A, Suzuki F, Kobayashi M, Mizokami M, Tanaka Y, Okanoue T, Minami M, Chayama K, Imamura M, Yatsuhashi H, Nagaoka S, Yotsuyanagi H, Kawata S, Kimura T, Maki N, Iino S, Kiyosawa K; HBV Core-Related Antigen Study Group. Tanaka E, et al. Among authors: chayama k. Liver Int. 2006 Feb;26(1):90-6. doi: 10.1111/j.1478-3231.2005.01200.x. Liver Int. 2006. PMID: 16420514
Emergence of a novel lamivudine-resistant hepatitis B virus variant with a substitution outside the YMDD motif.
Yatsuji H, Noguchi C, Hiraga N, Mori N, Tsuge M, Imamura M, Takahashi S, Iwao E, Fujimoto Y, Ochi H, Abe H, Maekawa T, Tateno C, Yoshizato K, Suzuki F, Kumada H, Chayama K. Yatsuji H, et al. Among authors: chayama k. Antimicrob Agents Chemother. 2006 Nov;50(11):3867-74. doi: 10.1128/AAC.00239-06. Epub 2006 Sep 18. Antimicrob Agents Chemother. 2006. PMID: 16982790 Free PMC article.
Low serum level of hepatitis B core-related antigen indicates unlikely reactivation of hepatitis after cessation of lamivudine therapy.
Matsumoto A, Tanaka E, Minami M, Okanoue T, Yatsuhashi H, Nagaoka S, Suzuki F, Kobayashi M, Chayama K, Imamura M, Yotsuyanagi H, Nakaoka S, Maki N, Kawata S, Kumada H, Iino S, Kiyosawa K. Matsumoto A, et al. Among authors: chayama k. Hepatol Res. 2007 Aug;37(8):661-6. doi: 10.1111/j.1872-034X.2007.00094.x. Hepatol Res. 2007. PMID: 17584261
Effects of a 24-week course of interferon-alpha therapy after curative treatment of hepatitis C virus-associated hepatocellular carcinoma.
Jeong SC, Aikata H, Katamura Y, Azakami T, Kawaoka T, Saneto H, Uka K, Mori N, Takaki S, Kodama H, Waki K, Imamura M, Shirakawa H, Kawakami Y, Takahashi S, Chayama K. Jeong SC, et al. Among authors: chayama k. World J Gastroenterol. 2007 Oct 28;13(40):5343-50. doi: 10.3748/wjg.v13.i40.5343. World J Gastroenterol. 2007. PMID: 17879404 Free PMC article.
Successful treatment of an entecavir-resistant hepatitis B virus variant.
Yatsuji H, Hiraga N, Mori N, Hatakeyama T, Tsuge M, Imamura M, Takahashi S, Fujimoto Y, Ochi H, Abe H, Maekawa T, Suzuki F, Kumada H, Chayama K. Yatsuji H, et al. Among authors: chayama k. J Med Virol. 2007 Dec;79(12):1811-7. doi: 10.1002/jmv.20981. J Med Virol. 2007. PMID: 17935165
Prospective study of short-term peginterferon-alpha-2a monotherapy in patients who had a virological response at 2 weeks after initiation of interferon therapy.
Jeong S, Kawakami Y, Kitamoto M, Ishihara H, Tsuji K, Aimitsu S, Kawakami H, Uka K, Takaki S, Kodama H, Waki K, Imamura M, Aikata H, Takahashi S, Chayama K. Jeong S, et al. Among authors: chayama k. J Gastroenterol Hepatol. 2008 Apr;23(4):541-5. doi: 10.1111/j.1440-1746.2008.05356.x. J Gastroenterol Hepatol. 2008. PMID: 18397484 Clinical Trial.
1,569 results